Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications
Journal of Clinical Medicine · 23.06.2026 · 15 (13) · 4852
DOI: 10.3390/jcm15134852 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 23.06.2026. Verfasst von Mohanad Almaimani und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, College of Medicine, University of Jeddah, Jeddah 23218, Saudi Arabia. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mineralocorticoid receptor (MR) overactivation is a key driver of inflammation, fibrosis, and organ cross-talk across cardiorenal disease. Finerenone, a selective non-steroidal MR antagonist, has demonstrated robust renoprotective and cardioprotective benefits in patients with chronic kidney disease (CKD) and type 2 diabetes in large randomized clinical trials. Beyond its established role in diabetic kidney disease, emerging preclinical and clinical data suggest potential systemic effects through the attenuation of MR-driven inflammatory and fibrotic pathways. These include signals related to heart failure outcomes, atrial remodeling, pulmonary vascular biology, retinal microvascular integrity, and metabolic dysfunction. However, much of the evidence beyond established cardiorenal indications remains exploratory, based on preclinical studies, subgroup analyses, and post hoc evaluations. This review provides a critical synthesis of the established clinical evidence supporting finerenone in CKD and cardiovascular disease. It examines emerging, hypothesis-generating data regarding its potential systemic effects beyond diabetic kidney disease.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, College of Medicine, University of Jeddah, Jeddah 23218, Saudi Arabia.
- King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
ORCID-Profile: Mohanad Almaimani
Zitieren
APA
Almaimani, M., & Alamri, S. A. (2026). Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications. Journal of Clinical Medicine, 15(13), 4852. https://doi.org/10.3390/jcm15134852
Vancouver
Almaimani M, Alamri SA. Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications. Journal of Clinical Medicine. 2026;15(13):4852. doi:10.3390/jcm15134852
BibTeX
@article{Almaimani2026,
author = {Almaimani, Mohanad and Alamri, Sadin Ayman},
title = {Finerenone Beyond Diabetic Kidney Disease: Emerging Evidence and Potential Systemic Implications},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {13},
pages = {4852},
doi = {10.3390/jcm15134852}
}
EUVIMED